MX364633B - Uso de cannabinoides en el tratamiento de enfermedades degenerativas del músculo esquelético. - Google Patents

Uso de cannabinoides en el tratamiento de enfermedades degenerativas del músculo esquelético.

Info

Publication number
MX364633B
MX364633B MX2017004761A MX2017004761A MX364633B MX 364633 B MX364633 B MX 364633B MX 2017004761 A MX2017004761 A MX 2017004761A MX 2017004761 A MX2017004761 A MX 2017004761A MX 364633 B MX364633 B MX 364633B
Authority
MX
Mexico
Prior art keywords
cannabinoids
skeletal muscle
treatment
muscle diseases
degenerative skeletal
Prior art date
Application number
MX2017004761A
Other languages
English (en)
Other versions
MX2017004761A (es
Inventor
Stott Colin
Foster Keith
Di Marzo Vicenzo
Iannotti Fabio
Original Assignee
Gw Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gw Pharma Ltd filed Critical Gw Pharma Ltd
Publication of MX2017004761A publication Critical patent/MX2017004761A/es
Publication of MX364633B publication Critical patent/MX364633B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere al uso de cannabinoides en el tratamiento de una enfermedad degenerativa del músculo esquelético. En particular, la enfermedad degenerativa del músculo esquelético es distrofia muscular de Duchenne (DMD). Preferiblemente, los cannabinoides son uno o más de: cannabidiol (CBD); cannabidivarina (CBDV) y tetrahidrocannabivarina (THCV).
MX2017004761A 2014-10-14 2015-10-14 Uso de cannabinoides en el tratamiento de enfermedades degenerativas del músculo esquelético. MX364633B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1418172.1A GB2531283A (en) 2014-10-14 2014-10-14 Use of cannabidiols in the treatment of degenerative skeletal muscle diseases
PCT/GB2015/053044 WO2016059411A1 (en) 2014-10-14 2015-10-14 Use of cannabinoids in the treatment of degenerative skeletal muscle diseases

Publications (2)

Publication Number Publication Date
MX2017004761A MX2017004761A (es) 2017-07-27
MX364633B true MX364633B (es) 2019-05-03

Family

ID=52001394

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004761A MX364633B (es) 2014-10-14 2015-10-14 Uso de cannabinoides en el tratamiento de enfermedades degenerativas del músculo esquelético.

Country Status (11)

Country Link
US (1) US10226433B2 (es)
EP (1) EP3206681B1 (es)
JP (1) JP6655076B2 (es)
AU (1) AU2015332220B2 (es)
BR (1) BR112017007774A2 (es)
CA (1) CA2963211C (es)
ES (1) ES2732062T3 (es)
GB (1) GB2531283A (es)
IL (1) IL251530B (es)
MX (1) MX364633B (es)
WO (1) WO2016059411A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2018235079A1 (en) 2017-06-20 2018-12-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. CANNABIDIOLIC ACID ESTER COMPOSITIONS AND USES THEREOF
WO2019025474A1 (en) * 2017-08-02 2019-02-07 Centro Cardiologico Monzino S.p.A. MODULATION OF ENDOCANNABINOID SYSTEM AND USES IN THE CONTEXT OF INDUCED PLURIPOTENT STEM CELL-BASED APPLICATIONS AND THERAPY FOR CARDIOMYOPATHIES
CN113116869B (zh) * 2019-12-31 2022-08-23 汉义生物科技（北京）有限公司 一种预防和/或治疗抑郁的组合物
WO2021137224A1 (en) * 2020-01-01 2021-07-08 Epm Group, Inc. Cannabidiolic acid esters for treating muscular dystrophy
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
WO2022122904A1 (en) 2020-12-09 2022-06-16 Chanelle Mccoy Cbd Limited A delayed-release capsule of cannabidiol
WO2024043242A1 (ja) * 2022-08-23 2024-02-29 国立大学法人九州大学 Ｔｒｐｃ３／６／７チャネル活性化による強心作用を介した心不全治療

Also Published As

Publication number Publication date
EP3206681B1 (en) 2019-04-10
WO2016059411A1 (en) 2016-04-21
ES2732062T3 (es) 2019-11-20
CA2963211A1 (en) 2016-04-21
CA2963211C (en) 2023-09-05
GB201418172D0 (en) 2014-11-26
GB2531283A (en) 2016-04-20
AU2015332220A1 (en) 2017-04-20
JP2018502823A (ja) 2018-02-01
AU2015332220B2 (en) 2020-10-01
MX2017004761A (es) 2017-07-27
US10226433B2 (en) 2019-03-12
US20170304217A1 (en) 2017-10-26
JP6655076B2 (ja) 2020-02-26
IL251530B (en) 2019-10-31
NZ730985A (en) 2024-01-26
IL251530A0 (en) 2017-05-29
EP3206681A1 (en) 2017-08-23
BR112017007774A2 (pt) 2018-01-16

Similar Documents

Publication Publication Date Title
MX2017004761A (es) Uso de cannabinoides en el tratamiento de enfermedades degenerativas del musculo esqueletico.
MX2019000427A (es) Formas de dosificacion oral de cannabinoide de alta concentracion.
MX2019008337A (es) Uso de cannabinoides para el tratamiento de epilepsia.
EA201290975A8 (ru) Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии
EA201791299A1 (ru) Микроинкапсулированные композиции каннабиноидов
CO2019001043A2 (es) Composición de cannabis
NZ726746A (en) Stable cannabinoid formulations
CO7101245A2 (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido
PE20170931A1 (es) Nuevas normalizaciones y dispositivos medicos para la preparacion de plasma rico en plaquetas (prp) o concentrado de medula osea (bmc) solos o combinados con acido hialuronico
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
PH12016501965A1 (en) S1p modulator immediate release dosage regimen
BR112018007958A2 (pt) composições e métodos que usam um polifenol para a saúde musculoesquelética
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
EP4137147A3 (en) Uses of abaloparatide in reducing fracture risk
MX2020004232A (es) Composiciones de cannabinoides y sus metodos de uso.
MX2020012800A (es) Cannabinoides y usos de los mismos.
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112017026834A2 (pt) composição compreendendo vitaminas b e vitaminas c e seu uso
MX2018001965A (es) Formulaciones liquidas que contienen picosulfato y citrato de magnesio.
CO6731081A2 (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
MX2016006544A (es) Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas.
NZ756307A (en) Formulations of cannabinoids for the treatment of acne
BR112017007364A2 (pt) composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico
EP3270883A4 (en) Scalable vitamin composition unit dosage for the treatment of fat-soluble vitamin deficiencies
BR112016028402A2 (pt) toxina botulínica para uso no tratamento da paratonia

Legal Events

Date Code Title Description
FG Grant or registration